Ritonavir

Overview

Ritonavir, sold under the brand name Norvir, is an antiretroviral medication used along with other medications to treat HIV/AIDS. This combination treatment is known as highly active antiretroviral therapy (HAART). Ritonavir is a protease inhibitor, though it now mainly serves to boost the potency of other protease inhibitors. It may also be used in combination with other medications to treat hepatitis C and COVID-19. It is taken by mouth.[1–6] WP

Common side effects of ritonavir include nausea, vomiting, loss of appetite, diarrhea, and numbness of the hands and feet. Serious side effects include liver complications, pancreatitis, allergic reactions, and arrhythmias. Serious interactions may occur with a number of other medications including amiodarone and simvastatin. At low doses, it is considered to be acceptable for use during pregnancy. Ritonavir is of the protease inhibitor class. However, it is also commonly used to inhibit the enzyme that metabolizes other protease inhibitors. This inhibition allows lower doses of these latter medications to be used.[3][7][8] WP

Ritonavir was patented in 1989 and came into medical use in 1996. It is on the World Health Organization's List of Essential Medicines. Ritonavir capsules were approved as a generic medication in the United States in 2020.[9–13] WP

Uses, dosage and effects

HIV/AIDS

Ritonavir was initially approved in 1996 as a standalone antiretroviral protease inhibitor for the treatment of HIV-1 infection. Early pharmacokinetic and pharmacodynamic (PK-PD) observations revealed that while high-dose monotherapy (such as 600 mg twice daily) was effective at suppressing viral replication, it was associated with significant gastrointestinal toxicity and the rapid emergence of drug-resistant viral strains.[14][15] WP

However, researchers discovered that ritonavir is one of the most potent known inhibitors of the cytochrome P450 3A4 (CYP3A4) enzyme. Administering it at much lower doses (100–200 mg) significantly slows the metabolism of other co-administered drugs, boosting their plasma concentrations and extending their half-lives without causing severe side effects. Consequently, ritonavir's clinical application shifted; it is rarely used today for its independent antiviral activity. Instead, it is indicated almost exclusively as a pharmacokinetic enhancer (or "booster") in combination therapy alongside other, primary protease inhibitors (such as lopinavir, darunavir, or atazanavir) to improve their efficacy and reduce the pill burden for patients.[14][15][16] WP

COVID-19

The pharmacokinetic boosting property of ritonavir has been successfully repurposed for the treatment of COVID-19. It is co-packaged with nirmatrelvir, a SARS-CoV-2 main protease (3CLpro) inhibitor, under the brand name Paxlovid. In this combination regimen, ritonavir has no direct activity against SARS-CoV-2; rather, it inhibits the CYP3A4-mediated metabolism of nirmatrelvir, enhancing its systemic exposure to levels sufficient to halt viral replication. Clinical trials demonstrated that this combination significantly reduced the risk of hospitalization or death in high-risk patients when administered early (within five days of symptom onset), leading to emergency use authorizations and approvals by agencies such as the US Food and Drug Administration (FDA) and the World Health Organization (WHO).[14][15] WP

Hepatitis c

Ritonavir is also utilized as a pharmacokinetic booster in direct-acting antiviral regimens for the treatment of Hepatitis C (HCV). It is formulated in combination with paritaprevir and ombitasvir (and sometimes dasabuvir), where ritonavir boosts the systemic levels of paritaprevir to maintain effective antiviral concentrations, achieving high sustained virological response rates with a manageable safety profile.[14] WP

Risks and side effects

Side effects

When administered at the initially tested higher doses effective for anti-HIV therapy, the side effects of ritonavir are those shown below.[1] WP

• Asthenia, malaise[1] WP
• Diarrhea[1] WP
• Nausea and vomiting[1] WP
• Abdominal pain[1] WP
• Dizziness[1] WP
• Insomnia[1] WP
• Kidney failure[1] WP
• Sweating[1] WP
• Taste abnormality[1] WP
• Metabolic effects, including[1] WP
• Hypercholesterolemia[1] WP
• Hypertriglyceridemia[1] WP
• Elevated transaminases[1] WP
• Elevated creatine kinase[1] WP

Adverse drug reactions

Ritonavir exhibits hepatic activity. It induces CYP1A2 and inhibits CYP3A4 and CYP2D6. Concomitant therapy of ritonavir with a variety of medications may result in serious and sometimes fatal drug interactions.[17][18] WP

Due to it being a strong inhibitor (that causes at least a five-fold increase in the plasma AUC values, or more than 80% decrease in clearance) of both cytochrome P450 enzymes CYP2D6 and CYP3A4, ritonavir can severely potentiate and prolong the half-life and/or increase the blood concentration of phenobarbital, primidone, carbamazepine, phenytoin, PDE5 inhibitors like sildenafil, opioids such as hydrocodone, oxycodone, pethidine and fentanyl, antiarrhythmic agents such as amiodarone, propafenone and disopyramide, immunosuppressants such as tacrolimus, voclosporin and sirolimus, neuroleptics like lurasidone and pimozide, as well as some chemotherapeutic agents, benzodiazepines and some ergot derivatives. The FDA has issued a boxed warning for this type of drug interaction.[4][19][20] WP

CYP3A4 inducers can counteract the inhibiting effects of ritonavir and lead to drastically reduced levels of "boosted" drugs, increasing the risk of developing drug resistance. Other CYP3A4 inhibitors may have an additive effect with ritonavir, causing increased drug levels.[4] WP

Polymorphism and temporary market withdrawal

Ritonavir was originally dispensed as a capsule that did not require refrigeration. This contained a crystal form of ritonavir that is now called form I. However, like many drugs, crystalline ritonavir can exhibit polymorphism, i.e., the same molecule can crystallize into more than one crystal type, or polymorph, each of which contains the same repeating molecule but in different crystal packings/arrangements. The solubility and hence the bioavailability can vary in the different arrangements, and this was observed for forms I and II of ritonavir.[21][22] WP

During development—ritonavir was introduced in 1996—only the crystal form now called form I was found; however, in 1998, a lower free energy, more stable polymorph, form II, was discovered. This more stable crystal form was less soluble, which resulted in significantly lower bioavailability. The compromised oral bioavailability of the drug led to temporary removal of the oral capsule formulation from the market. As a consequence of the fact that even a trace amount of form II can result in the conversion of the more bioavailable form I into form II, the presence of form II threatened the ruin of existing supplies of the oral capsule formulation of ritonavir; and indeed, form II was found in production lines, effectively halting ritonavir production. Abbott withdrew the capsules from the market, and prescribing physicians were encouraged to switch to a Norvir suspension. It has been estimated that Abbott lost more than US$250 million as a result, and the incident is often cited as a high-profile example of disappearing polymorphs.[21–25] WP

In 1999, the company's research and development teams ultimately solved the problem by replacing the capsule formulation with a refrigerated gelcap. In 2000, Abbott received FDA-approval for a tablet formulation of lopinavir/ritonavir (Kaletra) which contained a preparation of ritonavir that did not require refrigeration. Ritonavir tablets produced in an amorphous (non-crystalline) solid dispersion by melt-extrusion were introduced commercially in 2010.[26][27][28] WP

Pharmacology

HIV protease binding

Ritonavir is a pseudo-C₂-symmetric peptidomimetic inhibitor of the HIV-1 protease. It acts as a tight-binding, active-site titrant with an inhibition constant (Kᵢ) of 15 pM. At a structural level, the P3 isopropylthiazolyl group of ritonavir projects directly into the enzyme's active site to form critical hydrophobic interactions with the side chain of the Valine-82 (V82) residue. Resistance to ritonavir occurs when the viral protease gene develops mutations that distort this binding pocket; these amino acid substitutions generally occur in a stepwise fashion at specific positions, including V82A, V82F, V82T, and V82S.[14][16][29] WP

CYP3A4 inhibition

Although initially developed as an antiviral, ritonavir is now primarily utilized as a pharmacokinetic enhancer (or "booster") because it is a highly potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. By inhibiting CYP3A4, ritonavir prevents the metabolic breakdown of co-administered drugs (such as nirmatrelvir or lopinavir), thereby increasing their plasma concentrations and extending their therapeutic efficacy.[14][15] WP

The structural key to this inhibition is the unsubstituted P2' 5-thiazolyl group of ritonavir; the unhindered nitrogen atom on this specific thiazole ring binds directly to the heme iron inside the CYP3A4 active site. Researchers have proposed four primary mechanisms by which ritonavir achieves its quasi-irreversible inactivation of CYP3A4:[15][29] WP

• Formation of a metabolic-intermediate complex (MIC) that coordinates tightly to the heme group.[15] WP
• Strong ligation of unmodified ritonavir directly to the heme iron.[15] WP
• Heme destruction followed by the formation of a heme-protein adduct.[15] WP
• Covalent attachment of a reactive ritonavir intermediate directly to the CYP3A4 apoprotein, specifically at the Lysine-257 (Lys257) residue.[15] WP

Current evidence suggests ritonavir likely exerts its potent inhibitory effects through a mixed mechanism involving several of these pathways simultaneously.[15] WP

In addition to CYP3A4 inhibition, ritonavir induces the expression of several other enzymes (including CYP1A2, CYP2B6, CYP2C9, and CYP2C19) via the activation of the pregnane X receptor (PXR). It also acts as an inhibitor of key drug transporters, including P-glycoprotein (P-gp), Breast Cancer Resistance Protein (BCRP), and Organic Anion-Transporting Polypeptides (OATP1B1, OATP1B3, and OATP2B1).[14] WP

Absorption

The intestinal absorption of ritonavir requires an aqueous solubility threshold of greater than 1–2 µg/mL, which the drug achieves via an N-methylurea linker that allows it to be formulated for oral administration. The absolute bioavailability in humans has not been definitively established, though animal models indicate an absolute bioavailability between 74% and 76.4%.[14][29] WP

Distribution

Following a 600 mg oral dose, peak plasma concentrations (Cₘₐₓ) are achieved in approximately 2 hours under fasting conditions and 4 hours under non-fasting conditions. The presence of food alters absorption; the bioavailability of the tablet formulation decreases by 21–23% under moderate to high-fat conditions relative to fasting conditions.[14][16] WP

Ritonavir is highly bound (98–99%) to human serum proteins, primarily binding to serum albumin and α₁-acid glycoprotein over a concentration range of 0.01 to 30 µg/mL. This extensive protein binding attenuates its free antiviral activity in vitro by approximately 20-fold. The drug exhibits a volume of distribution (Vd) of 0.41 ± 0.25 L/kg.[14][16][29] WP

Metabolism

Ritonavir is extensively metabolized by the liver, driven predominantly by the CYP3A enzyme family, with minor contributions from CYP2D6. The biotransformation yields four major metabolites via pathways including N-demethylation, hydroxylation of the isopropyl side chain, and cleavage of the terminal thiazole groups. The primary metabolite is the isopropylthiazole oxidation metabolite (M-2), which retains antiviral activity comparable to the parent drug but circulates at very low plasma concentrations.[14][15][16] WP

Elimination

The drug exhibits non-linear pharmacokinetics. Upon multiple dosing, the accumulation of ritonavir is lower than predicted from a single dose, which is possibly due to a time- and dose-related increase in drug clearance. The circulating half-life of ritonavir is typically 3 to 5 hours.[14][16] WP

Elimination occurs primarily via the feces (86.4 ± 2.9%, with 33.8 ± 10.8% excreted as unchanged parent drug), while a smaller fraction is excreted in the urine (11.3 ± 2.8%, with 3.5 ± 1.8% as unchanged parent drug).[14][16] WP

History

History

Ritonavir is sold as Norvir by AbbVie, Inc. The US Food and Drug Administration (FDA) approved ritonavir on March 1, 1996, As a result of the introduction of "highly active antiretroviral thearap[ies]" the annual U.S. HIV-associated death rate fell from over 50,000 to about 18,000 over a period of two years.[1][2][30][31][32] WP

In 2014, the FDA approved a combination of ombitasvir/paritaprevir/ritonavir for the treatment of hepatitis C virus (HCV) genotype 4.[5] WP

After the start of the COVID pandemic in 2020, many antivirals, including protease inhibitors in general and ritonavir in particular, were repurposed in an effort to treat the new infection. Lopinavir/ritonavir was found not to work in severe COVID-19. Virtual screening followed by molecular dynamics analysis predicted ritonavir blocks the binding of the SARS-CoV-2 spike (S) protein to the human angiotensin-converting enzyme 2 (hACE2) receptor, which is critical for the virus entry into human cells.[33][34] WP

Finally in 2021, a combination of ritonavir with nirmatrelvir, a newly developed orally active 3C-like protease inhibitor, was developed for the treatment of COVID-19. Ritonavir serves to slow down metabolism of nirmatrelvir by cytochrome enzymes to maintain higher circulating concentrations of the main drug. In November that year, Pfizer announced positive phase 2/3 results, including 89% reduction in hospitalizations when given within three days after symptom onset.[35–41] WP

Legal status

Economics

In 2003, Abbott (AbbVie, Inc.) raised the price of a Norvir course from US$1.71 per day to US$8.57 per day, leading to claims of price gouging by patients' groups and some members of Congress. Consumer group Essential Inventions petitioned the NIH to override the Norvir patent, but the NIH announced on August 4, 2004, that it lacked the legal right to allow generic production of Norvir.[42] WP

Chemistry

Formula

C37H48N6O5S2 PC

CAS number

155213-67-5 PC

Molar mass (g/mol)

720.9 PC

IUPAC name (computed by PubChem)

1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate PC

SMILES

CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O PC

InChIKey

NCDNCNXCDXHOMX-XGKFQTDJSA-N PC

PubChem CID

392622

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Norvir- ritonavir tablet, film coated Norvir- ritonavir solution Norvir- ritonavir powder
2. Journal / agency Norvir EPAR. September 17, 2018
3. Other Ritonavir
4. Journal / agency Talha B, Dhamoon AS. StatPearls. 8 August 2023. PMID 31335032
5. Journal / agency FDA approves Viekira Pak to treat hepatitis C. December 19, 2014
6. Journal / agency Akinosoglou K, Schinas G, Gogos C. Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. Viruses. November 2022. doi:10.3390/v14112540 · PMID 36423149 · PMC9696049
7. Other Ritonavir Pregnancy and Breastfeeding Warnings
8. Other British National Formulary 69. March 31, 2015
9. Other Hacker M. Pharmacology principles and practice. 2009
10. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
11. Other World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. 2019
12. Other World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). 2021
13. Journal / agency Center for Drug Evaluation and Research. First Generic Drug Approvals. 2026-05-22
14. Journal / agency Pereira M, Vale N. Ritonavir's Evolving Role: A Journey from Antiretroviral Therapy to Broader Medical Applications. Current Oncology. October 2024. doi:10.3390/curroncol31100450 · PMID 39451754 · PMC11505664
15. Journal / agency Loos NH, Beijnen JH, Schinkel AH. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?. International Journal of Molecular Sciences. August 2022. doi:10.3390/ijms23179866 · PMID 36077262 · PMC9456214
16. Journal / agency NORVIR (ritonavir) Prescribing Information. 2017
17. Journal / agency Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Klein CE, Rublein JC, Kashuba AD. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. Journal of Acquired Immune Deficiency Syndromes. May 2006. doi:10.1097/01.qai.0000219774.20174.64 · PMID 16639344
18. Other Ritonavir: Drug Information Provided by Lexi-Comp: Merck Manual Professional. April 30, 2008
19. Journal / agency Stader F, Khoo S, Stoeckle M, Back D, Hirsch HH, Battegay M, Marzolini C. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. The Journal of Antimicrobial Chemotherapy. October 2020. doi:10.1093/jac/dkaa253 · PMID 32556272 · PMC7337877
20. Journal / agency Carpenter M, Berry H, Pelletier AL. Clinically Relevant Drug-Drug Interactions in Primary Care. American Family Physician. May 2019. PMID 31038898
21. Journal / agency Bauer J, Spanton S, Henry R, Quick J, Dziki W, Porter W, Morris J. Ritonavir: an extraordinary example of conformational polymorphism. Pharmaceutical Research. June 2001. doi:10.1023/A:1011052932607 · PMID 11474792
22. Journal / agency Morissette SL, Soukasene S, Levinson D, Cima MJ, Almarsson O. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proceedings of the National Academy of Sciences of the United States of America. March 2003. doi:10.1073/pnas.0437744100 · PMID 12604798 · PMC151315
23. Journal / agency Lüttge A. Crystal dissolution kinetics and Gibbs free energy. Journal of Electron Spectroscopy and Related Phenomena. February 1, 2006. doi:10.1016/j.elspec.2005.06.007
24. Journal / agency James JS. Ritonavir capsule manufacturing problems will require switch to liquid formulation. AIDS Treatment News. August 1998. PMID 11365685
25. Journal / agency Bučar DK, Lancaster RW, Bernstein J. Disappearing polymorphs revisited. Angewandte Chemie. June 2015. doi:10.1002/anie.201410356 · PMID 26031248 · PMC4479028
26. Journal / agency Ritonavir (Norvir): liquid or capsule. Research Initiative, Treatment Action. July 1999. PMID 11366721
27. Other Kaletra FAQ. 2011
28. Journal / agency Zhang C, Matzger AJ. A Newly Discovered Racemic Compound of Pioglitazone Hydrochloride Is More Stable than the Commercial Conglomerate. Crystal Growth & Design. February 2017. doi:10.1021/acs.cgd.6b01638 · PMID 31537981 · PMC6752731
29. Journal / agency Kempf DJ, Sham HL, Marsh KC, Flentge CA, Betebenner D, Green BE, McDonald E, Vasavanonda S, Saldivar A, Wideburg NE, Kati WM, Ruiz L, Zhao C, Fino L, Patterson J, Molla A, Plattner JJ, Norbeck DW. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. Journal of Medicinal Chemistry. February 1998. doi:10.1021/jm970636+ · PMID 9484509
30. Journal / agency Ritonavir FDA approval package. March 1, 1996
31. Journal / agency FDA Approval of HIV Medicines
32. Journal / agency HIV surveillance--United States, 1981-2008. MMWR. Morbidity and Mortality Weekly Report. June 2011. PMID 21637182
33. Journal / agency Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England Journal of Medicine. May 2020. doi:10.1056/NEJMoa2001282 · PMID 32187464 · PMC7121492
34. Journal / agency Bagheri M, Niavarani A. Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. Journal of Biomolecular Structure & Dynamics. October 2020. doi:10.1080/07391102.2020.1830854 · PMID 33030105
35. Journal / agency Vandyck K, Deval J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Current Opinion in Virology. August 2021. doi:10.1016/j.coviro.2021.04.006 · PMID 34029993 · PMC8075814
36. Journal / agency Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang XQ, Clark AE, McMillan RE, Leibel SL, McVicar RN, Xie J, Garretson AF, Smith VI, Murphy J, Hostetler KY. Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs. Antimicrobial Agents and Chemotherapy. September 2021. doi:10.1128/AAC.01155-21 · PMID 34310217 · PMC8448143
37. Journal / agency Ahmad B, Batool M, Ain QU, Kim MS, Choi S. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. International Journal of Molecular Sciences. August 2021. doi:10.3390/ijms22179124 · PMID 34502033 · PMC8430524
38. Other Tirumalaraju D. Pfizer begins dosing in Phase II/III trial of antiviral drug for Covid-19. September 2, 2021
39. Other Woodley M. What is Australia's potential new COVID treatment?. October 19, 2021
40. Other Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study. November 5, 2021
41. Other Weintraub K. Pfizer antiviral drug could nearly end deaths from COVID-19, company study suggests. November 5, 2021
42. Other Connolly C. NIH Declines to Enter AIDS Drug Price Battle. August 5, 2004

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.